Pacific Biosciences of California (STU:P09) LT-Debt-to-Total-Asset : 0.53 (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Pacific Biosciences of California LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Pacific Biosciences of California's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.53.

Pacific Biosciences of California's long-term debt to total assets ratio declined from Dec. 2023 (0.53) to Dec. 2024 (0.53). It may suggest that Pacific Biosciences of California is progressively becoming less dependent on debt to grow their business.

Pacific Biosciences of California LT-Debt-to-Total-Asset Historical Data

The historical data trend for Pacific Biosciences of California's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California LT-Debt-to-Total-Asset Chart

Pacific Biosciences of California Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.09

0.47

0.53

Pacific Biosciences of California Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.53	0.55	0.60	0.63	0.53

Pacific Biosciences of California LT-Debt-to-Total-Asset Calculation

Pacific Biosciences of California's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	632.6	/	1203.727
	=	0.53

Pacific Biosciences of California's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	632.6	/	1203.727
	=	0.53

Pacific Biosciences of California (STU:P09) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Pacific Biosciences of California LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (STU:P09) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

PACB:USA P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.

Pacific Biosciences of California Headlines

No Headlines